Congratulations to YSB Inc. (9885.HK) on its Successful Listing

 

Congratulations to YSB Inc. (9885.HK) on its Successful Listing on the Mainboard of HKSE on 28 June 2023

 

Founded in 2015, YSB Inc. is the digital pharmaceutical platform serving businesses outside of hospitals in China.

 

The Company is committed to using digitalization to empower participants in the out-of-hospital pharmaceutical market, including pharmaceutical companies, distributors, vendors, pharmacies and primary healthcare institutions, and strives to bring pharmaceutical health products and services to the downstream in a safe and efficient way, so that users can easily obtain a large number of comprehensive and high-quality drugs at a fair and transparent price. With the mission of building a safer and more efficient trading and service platform for the pharmaceutical industry, YSB drives the improvement of the overall efficiency of the medical and health ecosystem.

 

According to Frost & Sullivan, as of December 31, 2022, YSB has established the largest digital pharmaceutical trading and service network, including approximately 354,000 downstream pharmacies and approximately 173,000 primary healthcare institutions. Furthermore, YSB had 308,000 average number of monthly active buyers in 2022 and the average number of monthly available stock keeping units transacted on their platform was around 3.3 million in 2022, which is the highest among digital pharmaceutical platforms serving businesses outside of hospitals in China.

 

With regard to this listing application, AVISTA Group is honored to be engaged in providing valuation services in relation to purchase price allocation, financial instruments, stock options, assets impairment assessment and expected credit loss for financial reporting purposes.

 

Congratulations again to YSB Inc. (9885.HK) on its successful listing. The issue price is HKD 20 per share, and the amount of funds raised is HKD 215 million.